首页> 美国卫生研究院文献>The Journal of Headache and Pain >Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 EVOLVE-2)

【2h】

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 EVOLVE-2)

机译：校正为：发作性偏头痛中的Galcanezumab：在3期研究（EVOLVE-1和EVOLVE-2）中按偏头痛高发和低频发生的亚组疗效分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The overall least-squares (LS) mean change in Migraine Disability Assessment (MIDAS) total Score for the average of Months 3 and 6 is shown for patients with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The LS mean changes in MIDAS total score at Months 3 and 6 for patients receiving these treatments is shown in the bottom row for patients with LFEM and with HFEM. *** ≤ .001, ** ≤ .01, * ≤ .05 vs placebo

机译：LFEM和HFEM患者接受安慰剂，120 mg或240 mg加尔珠单抗治疗后的第3个月和第6个月平均值的偏头痛残疾评估（MIDAS）总分的总体最小二乘（LS）平均变化显示。上排。 LFEM和HFEM患者的底行显示了接受这些治疗的患者在第3和第6个月MIDAS总评分的LS平均变化。 ***≤.001，**≤.01，*≤.05 vs安慰剂

著录项

期刊名称 The Journal of Headache and Pain
作者
Stephen D. Silberstein; Virginia L. Stauffer; Katie A. Day; Sarah Lipsius; Maria-Carmen Wilson;
展开▼
作者单位

展开▼
年(卷),期 2019(20),1
年度 2019
页码 -1
总页数 2
原文格式 PDF
正文语种
中图分类神经科学;神经病学;
关键词

相似文献

外文文献
中文文献
专利

1. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) [J] . Stephen D. Silberstein, Virginia L. Stauffer, Katie A. Day, The journal of headache and pain . 2019,第1期

机译：在eGisodic偏头痛中的Galcanezumab：亚群分析效果的高与低频偏头痛在第3期研究中（Evolve-1和Evolve-2）
2. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies [J] . Stefanie F?rderreuther, Qi Zhang, Virginia L. Stauffer, The journal of headache and pain . 2018,第1期

机译：Galcanezumab在成年患者中的预防疗效患者持久性：来自第3阶段，随机，双盲，安慰剂控制的进化-1，进化-2和重新研究
3. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post‐Hoc Analyses on the First 3 Weeks of Treatment [J] . Silberstein Stephen D., Rapoport Alan M., Loupe Pippa S., Headache . 2019,第3期

机译：从弗里曼扎姆布开始治疗对高频术偏头痛的随机阶段2研究中的头痛和相关症状的影响：治疗前3周后HOC分析
4. A Hemispherical Sparse Phased Array Design For Low Frequency Transcranial Focused Ultrasound Applications Without Skull-Specific Phase Aberration Correction [C] . Xiangtao Yin, Kullervo Hynynen International Symposium on Therapeutic Ultrasound . 2006

机译：用于低频经颅重聚焦超声应用的半球形稀疏序列阵列设计，无需头骨特定的相位像差校正
5. Investigating physiological and psychological differences between migraine without aura and frequent episodic tension-type headache: Contingent negative variation and habituation. [D] . Delli Colli, Kellie M. 2011

机译：研究无先兆偏头痛和频繁发作的紧张型头痛之间的生理和心理差异：或有负性变化和习惯。
6. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 EVOLVE-2) [O] . Stephen D. Silberstein, Virginia L. Stauffer, Katie A. Day, 2019

机译：Galcanezumab在发作性偏头痛中的作用：在3期研究（EVOLVE-1和EVOLVE-2）中按偏头痛高发和低频发生的亚组分析
7. Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 EVOLVE-2) [O] . Stephen D. Silberstein, Virginia L. Stauffer, Katie A. Day, 2019

机译：校正至：Galcanezumab在eGisodic偏头痛中：亚群对阶段3研究中的高偏头痛的疗效分析（进化-1和Evolve-2）

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 EVOLVE-2)

摘要

著录项

相似文献

相关主题

期刊订阅